Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer

Takeshita, Michinori; Koga, Tomohiro; Takayama, K.; Yano, Tokujiro; Maehara, Yoshihiko; Nakanishi, Yoichi; Sueishi, Katsuo

doi:10.4161/cbt.10.9.13320

Cited by 13 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Checkpoint gene with forkhead-associated domain and ring finger gene methylation is significantly related to high sensitivity to paclitaxel. 78 A preclinical study with NSCLC cell lines suggested high ATP binding cassette B1(ABCB1) mRNA expression as a predictive biomarker for poor chemosensitivity to paclitaxel. 79 High beta-3 tubulin expression is correlated with poor prognosis and resistance to chemotherapy in general, but lacks a specific predictive value for paclitaxel versus gemcitabine.…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

Gupta¹,

Hatoum²,

Dy³

2013

IJN

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of cases. Paclitaxel has a broad spectrum of activity against various malignancies, including NSCLC. Paclitaxel is poorly soluble in water and thus, until recently, its commercially available preparations contained a non-ionic solvent Cremophor EL®. Cremophor EL® improves the solubility of paclitaxel and allows its intravenous administration. However, certain side-effects associated with paclitaxel, such as hypersensitivity reactions, myelosuppression, and peripheral neuropathy, are known to be worsened by Cremophor®. Nanoparticle albumin-bound paclitaxel ([nab-paclitaxel] ABRAXANE® ABI-007) is a new generation formulation of paclitaxel that obviates the need for Cremophor®, resulting in a safer and faster infusion without requiring the use of premedications to avoid hypersensitivity. Albumin-binding receptor-mediated delivery and lack of sequestering Cremophor® micelles allow higher intratumoral concentration of pharmacologically active paclitaxel. Multiple clinical trials have demonstrated a superior tolerability profile of nab-paclitaxel in comparison to solvent-bound paclitaxel (sb-paclitaxel). A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. This trial highlights the weekly nab-paclitaxel combination as an alternate treatment option for NSCLC, with higher response rate in squamous cell NSCLC and longer survival in elderly patients. This review will focus on the properties of nab-paclitaxel and its use in the first line treatment of NSCLC.

show abstract

Section: Conclusion and Future Perspectivementioning

confidence: 99%

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

Gupta¹,

Hatoum²,

Dy³

2013

IJN

View full text Add to dashboard Cite

show abstract

“…As discussed by Takeshita et al the invasiveness of the procedure necessary to determine CHFR promoter methylation status in lung cancers (and likely other solid tumors as well) make CHFR-based predictions less than ideal in NSCLC. 22 This indicates the importance of finding alternate indicators for drug response. Takeshita et al observed a significant correlation between wild-type EGFR and paclitaxel response, 22 which might also be useful in the absence of CHFR methylation status data.…”

mentioning

confidence: 99%

“…22 This indicates the importance of finding alternate indicators for drug response. Takeshita et al observed a significant correlation between wild-type EGFR and paclitaxel response, 22 which might also be useful in the absence of CHFR methylation status data.…”

mentioning

confidence: 99%

“…This represents a powerful tool by which physicians can choose the most effective treatment for their patients. In this issue, a strong correlation between CHFR loss and sensitivity to microtubule drugs such as paclitaxel has been demonstrated in NSCLC, 22 suggesting that CHFR promoter methylation could be used as a predictive marker of drug response. However, work by Yoshida et al suggests that, in advanced and recurrent gastric cancer, CHFR promoter methylation does not predict response to paclitaxel.…”

mentioning

confidence: 99%

“…In the current issue of Cancer Biology & Therapy, Takeshita et al present evidence that the combination of CHFR methylation status, EGFR mutation status and patient smoking habit can more effectively predict tumor response to paclitaxel treatment in NSCLC. 22 CHFR promoter methylation alone may not be informative enough as a predictor of chemoresponsiveness in all cancers. As discussed by Takeshita et al the invasiveness of the procedure necessary to determine CHFR promoter methylation status in lung cancers (and likely other solid tumors as well) make CHFR-based predictions less than ideal in NSCLC.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?

Keller¹,

Erson-Bensan²,

Petty³

2010

Cancer Biology & Therapy

View full text Add to dashboard Cite

CHFR: a key checkpoint component implicated in a wide range of cancers

Sanbhnani

Yeong

2011

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

CHFR (Checkpoint with Forkhead-associated and RING finger domains) has been implicated in a checkpoint regulating entry into mitosis. However, the details underlying its roles and regulation are unclear due to conflicting lines of evidence supporting different notions of its functions. We provide here an overview of how CHFR is thought to contribute towards regulating mitotic entry and present possible explanations for contradictory observations published on the functions and regulation of CHFR. Furthermore, we survey key data showing correlations between promoter hypermethylation or down-regulation of CHFR and cancers, with a view on the likely reasons why different extents of correlations have been reported. Lastly, we explore the possibilities of exploiting CHFR promoter hypermethylation status in diagnostics and therapeutics for cancer patients. With keen interest currently focused on the association between hypermethylation of CHFR and cancers, details of how CHFR functions require further study to reveal how its absence might possibly contribute to tumorigenesis.

show abstract

Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer

Cited by 13 publications

References 29 publications

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?

CHFR: a key checkpoint component implicated in a wide range of cancers

Contact Info

Product

Resources

About

Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer

Cited by 13 publications

References 29 publications

First line treatment of advanced non-small-cell lung cancer &ndash; specific focus on albumin bound paclitaxel

First line treatment of advanced non-small-cell lung cancer &ndash; specific focus on albumin bound paclitaxel

Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?

CHFR: a key checkpoint component implicated in a wide range of cancers

Contact Info

Product

Resources

About

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel